{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-002888","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.346009+00:00","generated_at":"2026-06-07T03:12:14.556435+00:00","sec_items":["1.01","8.01","2.05"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allogene to start pivotal ALPHA3 trial in 1L LBCL; cuts 22% staff, partners with Foresight","bullets":["Workforce reduction of ~22% with estimated $5.0M-$5.5M in severance charges, mostly in Q1 2024.","Strategic collaboration with Foresight Diagnostics to develop MRD assay; Allogene to fund ~$26M.","Plans to initiate pivotal Phase 2 ALPHA3 trial mid-2024 for cema-cel in 1L LBCL, targeting MRD+ patients (n~230).","Deprioritizing 3L trials ALPHA2 and EXPAND; expects CD19 CAR T 2L/3L market to diminish."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-002888","json":"https://secwatch.observer/filing/0001193125-24-002888.json","markdown":"https://secwatch.observer/filing/0001193125-24-002888.md","text":"https://secwatch.observer/filing/0001193125-24-002888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/d103673d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:12:14.556435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"473941ad39afdfce268e9a78b46a857bef515ea5","claim":"Allogene Therapeutics, Inc. entered into Strategic Collaboration Agreement with Foresight Diagnostics, Inc. (effective 2024-01-03).","evidence_excerpt":"On January 3, 2024, Allogene Therapeutics, Inc. (the “Company”) entered into a Strategic Collaboration Agreement (the “Agreement”) with Foresight Diagnostics, Inc. (“Foresight”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Foresight Diagnostics, Inc."},{"label":"Effective","value":"2024-01-03"}],"fact_type":"material_agreement"},{"claim_id":"121bce1de658afbeabbc8b94622400dac704b3db","claim":"Allogene Therapeutics, Inc. announced a restructuring with charges of reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical devel affecting workforce (approximately 22% of the Company’s employees).","evidence_excerpt":"On January 4, 2024, the Company’s Board of Directors approved a reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical development strategy.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"reduction in the Company’s workforce of approximately 22% of the Company’s employees in connection with the Company’s pipeline prioritization and clinical devel"},{"label":"Affected area","value":"workforce"},{"label":"Headcount","value":"approximately 22% of the Company’s employees"}],"fact_type":"restructuring_charge"},{"claim_id":"9b1ed7e14aa077e8c14dc2b65a06b91bb5f4be01","claim":"Allogene Therapeutics, Inc. announced a restructuring with charges of charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits affecting financial.","evidence_excerpt":"The Company estimates that it will incur charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits, primarily in the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312524002888/0001193125-24-002888-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"charges of approximately $5.0 million to $5.5 million for severance payments and employee benefits"},{"label":"Affected area","value":"financial"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}